Increased risk of chemotherapy-associated venous thromboembolism in elderly patients with cancer

Matteo Vergati, David Della-Morte, Patrizia Ferroni, Vittore Cereda, Livia Tosetto, Francesca La Farina, Fiorella Guadagni, Mario Roselli

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Data on the relationship between aging, chemotherapy, and risk for venous thromboembolism (VTE) are controversial. We sought to evaluate the risk of chemotherapy-associated VTE in young to middle-aged (YMA) and elderly cancer patients and to analyze the VTE-free survival time in both groups. Patients with histologically confirmed diagnosis of solid malignancy receiving any type of systemic chemotherapy, no clinical diagnosis of VTE before chemotherapy initiation, and Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2 were enrolled in this study. Of the 486 consecutive patients included in the study, 380 (78%) were classified as YMA (≤70 years of age) and 106 (22%) as elderly (>70 years of age). At a median follow-up of 1 year, the incidence of VTE events was almost two-fold greater in elderly than in YMA (11% vs. 6%). Age (≤70 years vs. >70 years (hazard ratio [HR], 2.42; 95% confidence interval [CI] 1.15-5.06; p=0.020), ECOG-PS (HR, 6.54; 95% CI 3.10-13.8; p

Original languageEnglish
Pages (from-to)224-231
Number of pages8
JournalRejuvenation Research
Volume16
Issue number3
DOIs
Publication statusPublished - Jun 1 2013

Fingerprint

Venous Thromboembolism
Drug Therapy
Neoplasms
Confidence Intervals
Survival
Incidence

ASJC Scopus subject areas

  • Ageing
  • Geriatrics and Gerontology

Cite this

Increased risk of chemotherapy-associated venous thromboembolism in elderly patients with cancer. / Vergati, Matteo; Della-Morte, David; Ferroni, Patrizia; Cereda, Vittore; Tosetto, Livia; La Farina, Francesca; Guadagni, Fiorella; Roselli, Mario.

In: Rejuvenation Research, Vol. 16, No. 3, 01.06.2013, p. 224-231.

Research output: Contribution to journalArticle

Vergati, Matteo ; Della-Morte, David ; Ferroni, Patrizia ; Cereda, Vittore ; Tosetto, Livia ; La Farina, Francesca ; Guadagni, Fiorella ; Roselli, Mario. / Increased risk of chemotherapy-associated venous thromboembolism in elderly patients with cancer. In: Rejuvenation Research. 2013 ; Vol. 16, No. 3. pp. 224-231.
@article{45725104432d4fc5a3f0ab69bb4d8ffd,
title = "Increased risk of chemotherapy-associated venous thromboembolism in elderly patients with cancer",
abstract = "Data on the relationship between aging, chemotherapy, and risk for venous thromboembolism (VTE) are controversial. We sought to evaluate the risk of chemotherapy-associated VTE in young to middle-aged (YMA) and elderly cancer patients and to analyze the VTE-free survival time in both groups. Patients with histologically confirmed diagnosis of solid malignancy receiving any type of systemic chemotherapy, no clinical diagnosis of VTE before chemotherapy initiation, and Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2 were enrolled in this study. Of the 486 consecutive patients included in the study, 380 (78{\%}) were classified as YMA (≤70 years of age) and 106 (22{\%}) as elderly (>70 years of age). At a median follow-up of 1 year, the incidence of VTE events was almost two-fold greater in elderly than in YMA (11{\%} vs. 6{\%}). Age (≤70 years vs. >70 years (hazard ratio [HR], 2.42; 95{\%} confidence interval [CI] 1.15-5.06; p=0.020), ECOG-PS (HR, 6.54; 95{\%} CI 3.10-13.8; p",
author = "Matteo Vergati and David Della-Morte and Patrizia Ferroni and Vittore Cereda and Livia Tosetto and {La Farina}, Francesca and Fiorella Guadagni and Mario Roselli",
year = "2013",
month = "6",
day = "1",
doi = "10.1089/rej.2013.1409",
language = "English",
volume = "16",
pages = "224--231",
journal = "Rejuvenation Research",
issn = "1549-1684",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Increased risk of chemotherapy-associated venous thromboembolism in elderly patients with cancer

AU - Vergati, Matteo

AU - Della-Morte, David

AU - Ferroni, Patrizia

AU - Cereda, Vittore

AU - Tosetto, Livia

AU - La Farina, Francesca

AU - Guadagni, Fiorella

AU - Roselli, Mario

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Data on the relationship between aging, chemotherapy, and risk for venous thromboembolism (VTE) are controversial. We sought to evaluate the risk of chemotherapy-associated VTE in young to middle-aged (YMA) and elderly cancer patients and to analyze the VTE-free survival time in both groups. Patients with histologically confirmed diagnosis of solid malignancy receiving any type of systemic chemotherapy, no clinical diagnosis of VTE before chemotherapy initiation, and Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2 were enrolled in this study. Of the 486 consecutive patients included in the study, 380 (78%) were classified as YMA (≤70 years of age) and 106 (22%) as elderly (>70 years of age). At a median follow-up of 1 year, the incidence of VTE events was almost two-fold greater in elderly than in YMA (11% vs. 6%). Age (≤70 years vs. >70 years (hazard ratio [HR], 2.42; 95% confidence interval [CI] 1.15-5.06; p=0.020), ECOG-PS (HR, 6.54; 95% CI 3.10-13.8; p

AB - Data on the relationship between aging, chemotherapy, and risk for venous thromboembolism (VTE) are controversial. We sought to evaluate the risk of chemotherapy-associated VTE in young to middle-aged (YMA) and elderly cancer patients and to analyze the VTE-free survival time in both groups. Patients with histologically confirmed diagnosis of solid malignancy receiving any type of systemic chemotherapy, no clinical diagnosis of VTE before chemotherapy initiation, and Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2 were enrolled in this study. Of the 486 consecutive patients included in the study, 380 (78%) were classified as YMA (≤70 years of age) and 106 (22%) as elderly (>70 years of age). At a median follow-up of 1 year, the incidence of VTE events was almost two-fold greater in elderly than in YMA (11% vs. 6%). Age (≤70 years vs. >70 years (hazard ratio [HR], 2.42; 95% confidence interval [CI] 1.15-5.06; p=0.020), ECOG-PS (HR, 6.54; 95% CI 3.10-13.8; p

UR - http://www.scopus.com/inward/record.url?scp=84879104516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879104516&partnerID=8YFLogxK

U2 - 10.1089/rej.2013.1409

DO - 10.1089/rej.2013.1409

M3 - Article

C2 - 23521603

AN - SCOPUS:84879104516

VL - 16

SP - 224

EP - 231

JO - Rejuvenation Research

JF - Rejuvenation Research

SN - 1549-1684

IS - 3

ER -